A Study of RC48-ADC in Subjects With Advanced Breast Cancer

NCT ID: NCT03052634

Last Updated: 2023-12-18

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 112 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-12-23
• Study Completion Date: 2023-04-07

Brief Summary

This study will evaluate the efficacy, safety and pharmacokinetics of RC48-ADC for injection in subjects with advanced breast cancer with HER2 positive or HER2 low expression

Conditions

Advanced Breast Cancer

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

RC48-ADC 1.5 mg/kg (HER2 Positive)

Group Type: EXPERIMENTAL

RC48-ADC 1.5 mg/kg (HER2 Positive)

Intervention Type: DRUG

15 advanced breast cancer participants with HER2 Positive will be treated with RC48-ADC at a dose of 1.5 mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.

RC48-ADC 2.0 mg/kg (HER2 Positive)

Group Type: EXPERIMENTAL

RC48-ADC 2.0 mg/kg (HER2 Positive)

Intervention Type: DRUG

15 advanced breast cancer participants with HER2 Positive will be treated with RC48-ADC at a dose of 2.0mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.

RC48-ADC 2.5 mg/kg (HER2 Positive)

Group Type: EXPERIMENTAL

RC48-ADC 2.5 mg/kg (HER2 Positive)

Intervention Type: DRUG

15 advanced breast cancer participants with HER2 Positive will be treated with RC48-ADC at a dose of 2.5 mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.

RC48-ADC 2.0 mg/kg (HER2 Low Expression)

Group Type: EXPERIMENTAL

RC48-ADC 2.0 mg/kg (HER2 Low Expression)

Intervention Type: DRUG

45 advanced breast cancer participants with HER2 Low Expression will be treated with RC48-ADC at a dose of 2.0 mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.

Interventions

RC48-ADC 1.5 mg/kg (HER2 Positive)

15 advanced breast cancer participants with HER2 Positive will be treated with RC48-ADC at a dose of 1.5 mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.

Intervention Type: DRUG

RC48-ADC 2.0 mg/kg (HER2 Positive)

15 advanced breast cancer participants with HER2 Positive will be treated with RC48-ADC at a dose of 2.0mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.

Intervention Type: DRUG

RC48-ADC 2.5 mg/kg (HER2 Positive)

15 advanced breast cancer participants with HER2 Positive will be treated with RC48-ADC at a dose of 2.5 mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.

Intervention Type: DRUG

RC48-ADC 2.0 mg/kg (HER2 Low Expression)

45 advanced breast cancer participants with HER2 Low Expression will be treated with RC48-ADC at a dose of 2.0 mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Voluntary signed informed consent;

2. Female, aged between 18 to 70 years;

3. ECOG performance status score of 0 or 1;

4. Life expectancy greater than 12 weeks；

5. Patients with locally advanced or metastatic breast cancer diagnosed by histology or cytology, and:

1. Core cohort: standard treatment is ineffective (the disease progresses or has no remission after treatment) or cannot tolerate standard treatment, or HER2 positive who cannot receive standard treatment (immunohistochemistry is 2+ and confirmed by fluorescence in situ hybridization [FISH] Positive, or immunohistochemical 3+) patients;

2. Explorative cohort:standard treatment is ineffective (the disease progresses or has no remission after treatment) or cannot tolerate standard treatment, or had no optional standard treatment for HER2 immunohistochemistry 2+ with FISH negative or HER2 immunohistochemistry 1+ (FISH negative or untested). Subjects in the explorative cohort can provide HER2 detection of tumor primary or metastatic site specimens;

6. Measurable lesion according to the RECIST 1.1;

7. Adequate organ function:

(1)absolute neutrophil count(ANC) >= 1.5 x 10(9)/L; (2) platelets>=100*10(9)/L; (3)Total serum bilirubin <=1.5*ULN; (4)serum aspartate transaminase (AST）and serum alanine transaminase (ALT) <=2.5*ULN, or AST and ALT<=5*ULN with hepatic metastasis; (5) Serum creatinine clearance rate >= 45 mL/min; (6) INR<=1.5*ULN and APTT<=1.5*ULN; 8.Women of child-bearing potential and men must agree to use adequate contraception (e.g., condoms, implants, injectables, combined oral contraceptives, some intrauterine devices, complete sexual abstinence, or sterilized partner) prior to study entry and during the period of therapy and for 6 months after the last dose of study drug; 9.Left ventricular ejection fraction (LVEF) >= 50%.

Exclusion Criteria

1. Women who are pregnant (positive blood test before medication) or breastfeeding;

2. Patients received anti-cancer therapy within 4 weeks before study drug treatment;, including chemotherapy, radiotherapy, surgery or hormone therapy, molecular targeted therapy (including trastuzumab etc.); Using Trastuzumab emtansine(T-DM1) or participating in the clinical trial on ADC drugs targeting HER2 and bispecific antibodies targeting HER2;

3. The patient have third interstitial fluid (a large number of pleural effusion or ascites) which has clinical symptom or can not be controlled by drainage or other methods;

4. Received Palliative radiation therapy for bone metastases within 2 weeks before study drug treatment;

5. Toxicity of previous anti-tumor treatment has not recovered to CTCAE [version 4.0] 0-1, except for hair loss;

6. Participated in other clinical trials within 4 weeks;

7. Known hypersensitivity or delayed hypersensitivity to the some components of RC48-ADC or similar drugs;

8. The active infection with clinical significance according to the researcher's judgment;

9. Diagnosed with HBsAg or HBcAb positive and HBV DNA positive, or HCV Ab positive, or HIV Ab positive.

10. Have a history of immunodeficiency, including a positive HIV test, or other acquired, congenital immunity Epidemic defects, or a history of organ transplantation;

11. Uncontrolled systemic diseases such as diabetes, hypertension, Pulmonary fibrosis, acute lung disease, interstitial lung disease, etc.

12. Congestive heart failure with grade 2 or higher (including grade 2) of the New York Institute of Cardiology (NYHA) of the United States in the history of diseases such as acute myocardial infarction, unstable angina, stroke, or transient ischemic attack within 6 months prior to entry ;

13. Insufficient adherence to participate in this clinical study;

14. Patients who had received systemic steroid therapy for a long time(Patients who had received systemic steroid therapy for short time and stopped drug more than 2 weeks could be enrolled );

15. Primary brain or metastatic tumor;

16. Peripheral neuropathy with grade≥2;

17. People with a history of mental illness that is difficult to control.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

RemeGen Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jianmin Fang

Role: STUDY_DIRECTOR

RemeGen Co., Ltd.

Locations

Cancer Hospital Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, China

The first bethune hospital of jilin unversity

Changchun, Jilin, China

Liaoning cancer hospital & institute

Shenyang, Liaoning, China

Zhejiang cancer hospital

Hangzhou, Zhejiang, China

Affiliated cancer hospital of Harbin medical university

Harbin, , China

The fourth hospital of Hebei medical university

Hebei, , China

Jiangsu Cancer Hospital

Nanjing, , China

Countries

China

Other Identifiers

C003 CANCER

Identifier Type: -

Identifier Source: org_study_id